Seastar Medical Holding Corp. (ICU) - 10-Q Summary
Business Context and Reporting Period
This summary covers the quarterly report (Form 10-Q) for the period ended September 30, 2025. Seastar Medical is a commercial-stage healthcare company developing the Selective Cytopheretic Device (SCD) to treat hyperinflammation. The company received FDA approval under a Humanitarian Device Exemption (HDE) for its pediatric product, QUELIMMUNE, in February 2024, with commercial shipments beginning in July 2024. The company is currently conducting a pivotal clinical trial for the adult version of the SCD.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Revenue | $183,000 | $68,000 | $814,000 | $68,000 |
| Gross Profit | $169,000 | $68,000 | $773,000 | $68,000 |
| Net Loss | $(3,472,000) | $(4,478,000) | $(9,246,000) | $(20,411,000) |
| Operating Expenses | $3,748,000 | $4,524,000 | $9,932,000 | $13,143,000 |
| Cash & Equivalents (End of Period) | $13,763,000 (Sep 30, 2025) | |||
| Accumulated Deficit | $(148,810,000) (Sep 30, 2025) | |||
| Working Capital | $10,808,000 (Sep 30, 2025) |
Note: All figures in thousands except per share data. The company had no outstanding notes payable as of September 30, 2025, having paid off previous obligations.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 169% quarter-over-quarter and 1,097% year-over-year (YTD), driven by the commercial launch of QUELIMMUNE. The company reported nine customer sites as of September 30, 2025.
- Expense Reduction: Total operating expenses decreased 17% QoQ and 24% YTD. This was achieved through reduced clinical trial costs, lower external consulting fees, and voluntary forfeiture of bonuses by employees and directors.
- Net Loss Improvement: The net loss narrowed significantly to $3.5 million for Q3 2025 from $4.5 million in Q3 2024. The YTD loss decreased by 55% compared to the prior year, largely due to the absence of a $6.1 million loss from the fair value adjustment of convertible notes recorded in 2024.
- Liquidity Position: Cash balances increased from $1.8 million at year-end 2024 to $13.8 million at September 30, 2025, following multiple equity offerings (February, June, July, and August 2025) and warrant exercises.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management explicitly states that cash on hand is insufficient to fund operations for the next 12 months. The filing raises substantial doubt about the company's ability to continue as a going concern without additional financing.
- Capital Requirements: The company plans to finance operations through equity sales, debt, or strategic collaborations. It has a $15 million Standby Equity Purchase Agreement (SEPA) with Lincoln Park Capital and an At-The-Market (ATM) facility, though the ATM is currently limited by shelf registration rules.
- Nasdaq Compliance: The company regained compliance with Nasdaq's Minimum Stockholders' Equity requirement in July 2025 but received a notice in late July 2025 regarding non-compliance with the $1.00 minimum bid price requirement. It has 180 days to regain compliance.
- Legal Proceedings: A putative securities class action lawsuit (Wells v. SeaStar Medical) is pending, alleging misstatements regarding FDA approval timing and financial restatements. A related derivative action is stayed pending the class action's resolution.
- Subsequent Events: Between October 1 and November 13, 2025, the company raised approximately $1.2 million via its ATM program. Additionally, a new $0.8 million short-term note was issued in October 2025 to finance D&O insurance.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" disclosure and the $13.8 million cash balance against ongoing burn rates.
- Commercial Traction: Confirm the number of active hospital sites and repeat order rates for QUELIMMUNE to assess if revenue can scale to cover operating costs.
- Nasdaq Status: Monitor the company's progress in meeting the $1.00 minimum bid price requirement to avoid delisting.
- Dilution Risk: Review the terms of the $15 million SEPA and recent warrant issuances (over 26 million equity-classified warrants outstanding) to understand potential dilution in future financings.
- Legal Exposure: Track the status of the Wells class action lawsuit and any potential settlement costs or impacts on management.